Kamil Ali-Jackson - 03 Jun 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Legal Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 03 Jun 2021
Net transactions value: -$208,421
Form type: 4
Filing time: 04 Jun 2021, 19:52:37 UTC
Previous filing: 02 Jun 2021
Next filing: 17 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Sale	$208,421	-9,492	-7.2%	$21.96	122,196	03 Jun 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.57 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.57 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.